WuXi AppTec’s Laboratory Testing Division is a comprehensive and integrated testing platform for drug and medical device development.
The Laboratory Testing Division provides in vivo and in vitro assays from early screening through clinical sample analysis, and medical device testing from development through product lifecycle management. We operate with full transparency, providing the high-quality data you need to advance your project while meeting international standards for regulatory compliance and maintaining industry-leading turnaround times.
The Laboratory Testing Division consists of two integrated testing platforms—WuXi AppTec IND (WIND) for Preclinical Drug Development and Medical Device Testing. Each platform is supported by the complementary capabilities of our three service units, which include Bioanalytical, Toxicology and DMPK services. Testing services are offered as a comprehensive package in support of global IND/NDA filings, or on a standalone basis, with customized study designs available to meet the varying needs of our diverse client base.
The Laboratory Testing Division is a unique, world-class, globally integrated testing powerhouse covering the entire clinical continuum from drug discovery to medical device to clinical diagnostic testing. We enable scientists to transform ideas into the best healthcare products, and ultimately improve human life.
Why WuXi AppTec?
As a fully integrated platform, the Laboratory Testing Division has the unique ability to test entire portfolios of compounds and accelerate our customers’ R&D efforts to bring innovative medicines to patients faster. With seven R&D sites in the U.S. and China and over 2,500 multidisciplinary employees worldwide, the Laboratory Testing Division is your partner of choice to take your project from lab to patient.
- Single testing solution from discovery through commercial
- Diverse knowledge fostered through communication and collaboration among teams
- Worldwide expertise paired with regional accessibility
- Global compliance with U.S. Food and Drug Administration (FDA), National Medical Products Administration (NMPA) and Organization for Economic Cooperation and Development (OECD)
- Flexible study designs to meet the needs of every customer and project
Seamless transfer of knowledge providing valuable insight beyond data alone
Headquartered in Shanghai, the Laboratory Testing Division has seven Research and Development (R&D) sites throughout China and the United States. Each facility operates in strict compliance with global regulatory requirements and maintains Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) accreditations for animal health and welfare where in vivo testing takes place.
- U.S. FDA
GLP Bioanalytical Lab
- U.S. FDA
GLP Toxicology Lab
- U.S. FDA
The Leadership Team
Steve Yang, Ph.D.
Executive Vice President, Chief Business Officer
Formerly Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, previous roles including Vice President and Head of R&D Asia at Pfizer. Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco.
Francis L. Tse, Ph.D.
Vice President & Chief Scientific Officer, New Jersey Site Head
Dr. Francis L. Tse has a wealth of experience in pharmaceutical development. Prior to joining WuXi AppTec, Dr. Tse served as Assistant Professor of Pharmacy at Rutgers University, then Vice President of Drug Metabolism & Bioanalytics at Novartis Pharma. Dr. Tse has published over 130 research articles and six books, including “Handbook of LC-MS Bioanalysis,” which has been translated into Chinese (Science Press, Beijing, 2017). Dr. Tse served on the Board of Directors of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQC), and is a Fellow of the American Association of Pharmaceutical Scientists (AAPS), Academy of Pharmaceutical Research and Science (APRS), and American College of Clinical Pharmacology (ACCP). In 2006, he received the prestigious Outstanding 50 Asian Americans in Business award. He received his B.S., M.S. and Ph.D. degrees from the University of Wisconsin-Madison.
Vice President of Operations
Hui Xu has over 20 years’ experience in operations and management for GLP facilities. As Vice President of Operations, she is fully responsible for the internal operations process and cross-function coordination with HQ. Prior to joining WuXi AppTec in 2008, Hui worked in a Chinese government laboratory for 17 years. Hui has extensive experience in toxicology and drug safety evaluations in China. Under her leadership, the team successfully passed a series of regulatory audits including FDA, OECD and CFDA GLP inspections, AAALAC inspections, internal QA audits and sponsor animal welfare audits. Hui actively participated in the development of the CFDA toxicology guidelines and the most recent revision of the CFDA GLP regulatory policy.
Xin Zhang, Ph.D.
Vice President & Global Head of DMPK, Bioanalysis & Abgent
Dr. Xin Zhang joined WuXi AppTec in September 2013. Prior to joining WuXi, Dr. Zhang worked for Charles River Laboratories, LabCorp (Tandem Labs) and Agilux Laboratories. After earning a degree in physical chemistry from Peking University and working in China for a few years, Dr. Zhang traveled to the US to pursue his graduate career and obtained his Ph.D. in organic chemistry from the University of Iowa. Dr. Zhang completed his postdoc training at Northeastern University, where he focused on new mass spectrometry applications including oligonucleotides, DNA adducts, and proteomics.
Vice President & Head of Toxicology
Bill Harrison has over 30 years’ experience in the contract research organization industry with a strong record of growth. Prior to joining WuXi AppTec, he was founder and CEO of VIDA Sciences, a company serving contract research organizations focusing on performance improvement. Earlier, Bill was President and COO of MPI Research, one of the largest preclinical providers in the world, where he led the company through a substantial growth period. Prior to MPI, Bill was Director of Regulatory Affairs and Operations at Pharmaco-LSR, now a part of Envigo. Bill is a former President of the US Society of Quality Assurance (SQA) and currently serves on the Board for the American Life Sciences Innovation Council. He earned a B.S. degree in biomedical engineering from the New Jersey Institute of Technology and has been an invited lecturer in North America, Japan, China and Australia.
Vice President of International Sales & Marketing
Ed Amat has over 27 years of successful performance in senior sales leadership, sales, marketing, public relations and client services in the pharmaceutical industry. Previously, Ed worked for MPI Research as Senior Director of Sales for North America and Europe, leading to Vice President of Global Sales and Marketing. At MPI, Ed led the commercial team, which sustained top-line YoY sales increase above company and industry rates. During his seven years at MPI, he also served on the executive leadership team supporting corporate decision making, direction and P&L management. Prior to MPI, Ed held pharmaceutical commercial functions at Pfizer and legacy companies, having been recognized with multiple sales and leadership awards. Ed is a former principal owner of a diagnostic medical testing company and recently served as a commercial officer with a drug manufacturing software company.